Six Micro-Caps Report August 17-21 With Listing Clocks and Financing Votes Already Running

by Kwame Osei · August 15, 2026

Market Structure Reporter, The MicroCap Herald

The week of August 17-21 belongs, in the coverage that most investors will see, to the American consumer. Home Depot, Target and Walmart all report, and the read-across from their gross margins will set the tone for the tape. Underneath that, a number of companies with market capitalisations below $500m are scheduled to report the same week, and for a handful of them the quarter is not the main event at all. It is the dated obligation sitting a few weeks behind it: a Nasdaq bid-price deadline, a shareholder vote on a reverse split, a covenant that has already been breached.

The MicroCap Herald verified six such names against the companies' own investor-relations announcements and their most recent filings. Each entry below states the reporting date, the timing relative to the session, the exchange, the ticker, and - where third-party sources agree on one - a market capitalisation with the date it was read. Where a company has going-concern language, a listing notice or a financing arrangement that dilutes existing holders, that is stated. Where it does not, that is stated too. Nothing here is a recommendation, a target or a view on value. Several names circulating on weekly earnings calendars for this period were excluded outright on size. Mercury Systems, OSI Systems, Daqo New Energy, Hovnanian Enterprises, Buckle, La-Z-Boy and Flex LNG are small- or mid-cap companies and do not belong in a micro-cap round-up, whatever the calendar says. Others - BitFuFu, Flexsteel, DocGo, uCloudlink, Prenetics, Hesai, Pony AI, Alvotech, LSI Industries, ScanSource and ZKH Group - were dropped because this desk could not independently verify the date, the timing and the size to its own standard in the time available. Twin Disc does report on Thursday, August 20, before the open - its own August 12 announcement puts the release at approximately 8:00 a.m. Eastern with a call at 9:00 a.m. - but is left out of the detail below.

The backdrop is a strong one for small caps as an asset class, which makes the company-specific problems below easier to overlook. The Russell 2000 closed Friday, August 14 at 3,068.42, a record, up 15.57 points or 0.51% on the day and about 1.1% on the week. The S&P 500 slipped 13.23 points, or 0.17%, to 7,785.76; the Nasdaq Composite fell 73.86 points, or 0.28%, to 26,729.16; and the Dow Jones Industrial Average fell 107.58 points, or 0.20%, to 53,732.41. An index at a record tells you nothing about whether an individual sub-$100m issuer has cured a covenant breach. The two questions are unrelated, and only the second one is answered in a filing.

Monday opens with InspireMD (Nasdaq: NSPR), a vascular-device company that will issue second-quarter results on August 17 and hold a call at 8:30 a.m. Eastern, per its August 10 announcement; the announcement does not say whether the release itself comes before or after the open. Shares closed at $0.98 on Friday, August 14, for a market capitalisation of about $46.0m, per WallStreetZen. This desk found no disclosure of a Nasdaq bid-price deficiency notice for InspireMD, and a single close below $1.00 does not create one: under Nasdaq's rules a deficiency notice follows 30 consecutive business days of closing bids below the $1.00 threshold.

What is on the record is the going-concern language. InspireMD's first-quarter report showed revenue of $3.398m and a net loss of $13.689m for the three months to March 31, 2026, against cash and cash equivalents of $11.362m and marketable securities of $30.208m. The company reported that loss as $0.16 per basic and diluted share, struck on a weighted average of 83,801,839 shares - a count well above the shares outstanding on the balance-sheet date, so the per-share figure cannot be reproduced from the cover-page count and the two should not be read against each other. Notwithstanding the securities balance, the quarterly report states plainly: "Therefore, there is substantial doubt about the Company's ability to continue as a going concern." The filing also says the company "does not have sufficient resources to fund operations for at least the next 12 months." Shares outstanding rose from 43,532,281 at December 31, 2025 to 46,838,963 at March 31, 2026.

Tuesday brings Evogene (Nasdaq: EVGN; TASE: EVGN), a computational-chemistry company that will release second-quarter results on August 18 with a call at 9:00 a.m. Eastern. StockTitan showed the shares at $0.6323 on August 10, 2026. Third-party market-capitalisation estimates for Evogene do not agree - StockTitan and StockAnalysis both put it near $7m on August 10, while public.com showed $10.29m on August 13 - and the company's own July 31 filing implies a larger share count than the lower estimates assume, so this desk states no single figure. On any of those readings Evogene is the smallest company in this round-up. First-quarter revenue fell to approximately $0.3m from approximately $2.3m a year earlier, the net loss widened to approximately $5.9m from approximately $3.0m, and consolidated cash use in the quarter was approximately $2.8m against consolidated cash, equivalents and short-term deposits of approximately $13.1m at March 31, 2026.

Evogene's first-quarter release did not contain going-concern language, but it did document a substantial retrenchment: Lavie Bio's operations ceased at the end of the first quarter, Biomica's lead oncology candidate licensed out to Lishan Pharmaceuticals, Casterra's activity significantly reduced and realigned to focus exclusively on Brazil, and the Bayer-AgPlenus herbicide development project discontinued after the target protein did not meet the required product criteria. The listing clock is explicit. On April 2, 2026 the company disclosed a Nasdaq notification under Rule 5550(a)(2), with a compliance deadline of September 28, 2026. The company said that "[s]hould the situation not resolve itself over the above-mentioned timeframe, the Company intends to consider other available options to cure the deficiency and regain compliance with the minimum bid requirement within the compliance period, including potentially approving a reverse stock split, among other alternatives."

That option goes to shareholders seventeen days after the earnings call. Evogene's July 31 filing sets an annual meeting for Friday, September 4, 2026, at which holders vote on authorising the board to execute a reverse split at a ratio between 1-for-2 and 1-for-15 within 18 months, and on increasing authorised share capital from NIS 6,000,000 (30,000,000 ordinary shares) to NIS 30,000,000 (150,000,000 ordinary shares). The same meeting carries a contested board election, with a slate of four nominees put forward by L.I.A Pure Capital Ltd. and Invest-Pro Shukai Hon Ltd., which the filing says held 2,308,100 ordinary shares, or 14.67% of the outstanding shares, as of July 21, 2026, against the company's seven-person slate.

Wednesday is the densest day of the week for this cohort, and it starts before the open with Datavault AI (Nasdaq: DVLT), which will report second-quarter results on August 19 prior to market open, with a call at 8:30 a.m. Eastern. It is the largest company here by market value: StockTitan showed the shares at $0.318 on August 14, 2026, for a market capitalisation of about $265.2m. First-quarter revenue was $3.416m, cash and cash equivalents stood at $2.205m at March 31, 2026, and the net loss attributable to common stockholders was $53.131m for the quarter.

The date that matters sits five days after the print. Datavault AI disclosed in an 8-K filed February 27, 2026 that it received a Nasdaq notice dated February 24 under Listing Rule 5550(a)(2), after the closing bid price stayed below $1.00 for 30 consecutive business days, giving it until August 24, 2026 to regain compliance. The filing states that "The Notice has no immediate effect on the listing of the Company's common stock on The Nasdaq Capital Market," and that if the company is not compliant by August 24 it "may be afforded a second 180 calendar day grace period" - conditional, not automatic, and turning on the company meeting Nasdaq's other listing standards apart from bid price and giving written notice of its intention to cure the deficiency by effecting a reverse stock split if necessary. Two further facts belong beside that. Shares issued and outstanding rose from 573,438,153 at December 31, 2025 to 617,813,176 at March 31, 2026, with approximately $29.985m raised through an at-the-market programme during the quarter. And the company has been down this road before under a different name: as WiSA Technologies, it executed a 1-for-150 reverse split effective April 12, 2024, with split-adjusted trading beginning April 15, 2024. All share figures cited here are on the current, post-2024-split basis.

Wednesday also brings Accuray (Nasdaq: ARAY), the radiation-oncology systems maker, which reports fourth-quarter and full-year fiscal 2026 results on August 19; the call is at 4:30 p.m. Eastern, after the close, and the fiscal year ended June 30. Accuray is a micro-cap on the current numbers, and the two readings available do not come from the same day: public.com put its market capitalisation at $32.91m as of August 13, 2026, while StockAnalysis showed the shares at $0.2850 on August 7, 2026 across roughly 119m shares, with a 52-week decline of 78.24%. Those are separate observations on separate dates and are not interchangeable.

The filings behind that are where the week's heaviest disclosure sits. Accuray reported total net revenue of $104.8m for the fiscal third quarter, and its balance sheet showed cash and cash equivalents of $38.067m at March 31, 2026 against short-term debt of $11.160m and long-term debt of $134.020m. On August 12, 2026 the company filed a preliminary proxy statement seeking approval for a $55.0m recapitalisation: $15.0m of cash already funded plus $40.0m of existing debt exchanged into equity, issued as 55,000 Series A Preferred shares at $1,000 each, alongside warrants over approximately 15.3m common shares at a $0.01 exercise price. Holders are also asked to double authorised common stock from 200,000,000 to 400,000,000 shares and to approve a reverse split at a ratio between 1-for-15 and 1-for-40. The special meeting is set for October 6, 2026.

The dilution arithmetic is disclosed rather than inferred: full conversion could add up to 125.3m new common shares, with up to 110,000,000 of those coming from the preferred alone - against roughly 119m shares outstanding, all on a pre-reverse-split basis. If holders do not approve, the proxy states the Series A Preferred would not be issued, the $40.0m debt exchange would not occur, and a $15.0m fee plus the $15.0m cash investment would become secured obligations under the financing agreement. Separately, Accuray received a Nasdaq bid-price notice on February 2, 2026 under Listing Rule 5550(a)(2), with an initial deadline of August 3; its listing transferred to the Nasdaq Capital Market effective August 6, 2026 and Nasdaq granted an additional 180 days, to February 1, 2027, to regain compliance.

Unifi (NYSE: UFI) is the outlier in this group in a useful way. The maker of Repreve recycled yarns will release fourth-quarter fiscal 2026 results after the close on Wednesday, August 19 and hold its call at 8:30 a.m. Eastern on Thursday, August 20. StockAnalysis put its market capitalisation at $113.85m on July 23, 2026 with the shares at $6.13. For the quarter ended March 29, 2026 it reported net sales of $130.037m and a net loss of $2.306m, narrowing a nine-month loss to $23.4m from $35.8m, with cash and equivalents of $26.6m and total debt of $94.9m - $60.1m on the ABL Term Loan, $22.0m on the 2024 Facility, $3.2m drawn on the ABL Revolver and $9.6m of finance lease obligations. This desk found no going-concern language and no disclosed covenant breach in that filing, and Unifi is the only one of the six with no listing-compliance deadline of any kind on the record.

Thursday closes the week with Flux Power (Nasdaq: FLUX), which reports fourth-quarter and full-year fiscal 2026 results on August 20 after market close, with a call at 4:30 p.m. Eastern; its fiscal year ends June 30. StockTitan showed the shares at $0.595 at the August 14, 2026 close, for a market capitalisation of about $12.5m. The third quarter was severe: revenue fell to $6.6m from $16.7m a year earlier, the net loss widened to $3.2m from $1.9m, and cash stood at $0.4m at March 31, 2026 against $1.3m at June 30, 2025, with $5.7m drawn on the line of credit. The quarterly report states that "substantial doubt exists about the Company's ability to continue as a going concern over the 12 months."

Flux Power also has the only disclosed covenant breach among these six. A prospectus filed April 3, 2026 disclosed that the company failed the minimum EBITDA financial covenant under its loan agreement with Gibraltar Business Capital for the trailing three-month period ended March 31, 2026, an event of default under an agreement with an outstanding balance of approximately $6.5m at that date. The lender has continued to allow access to the line of credit while an amendment or waiver is negotiated, and the filings say it can limit that access at any time; as of the company's June 4, 2026 prospectus no amendment or waiver had been completed, and this desk found no later disclosure that one has been. On top of that sits a Nasdaq notice dated July 24, 2026 under Rule 5550(a)(2), starting a 180-day compliance period, with the stock at $0.51 on July 29, 2026. And a June 4, 2026 prospectus registers up to 38,461,538 shares for resale under a $40m committed equity facility with Roth Principal Investments - against 21,361,383 shares outstanding as of May 15, 2026 - warning that any such issuance "could cause additional substantial dilution to our stockholders."

One macro item lands in the middle of it. The Federal Reserve releases the minutes of the July 28-29 FOMC meeting at 2:00 p.m. Eastern on Wednesday, August 19, per the Board's own August calendar - the same day that Datavault AI reports before the open and Accuray and Unifi report after the close. For companies funding losses with equity issuance and asset-based credit, the path of policy rates is a live input into the cost of both. Nothing in the minutes will change a covenant test or move a listing deadline, but it will be read alongside them.

For readers following these six, the disclosures worth reading are the ones that rarely make the headline number: the going-concern paragraph and its exact wording, the covenant compliance discussion, the cash and equivalents line next to the quarter's operating burn, the shares-outstanding count on the cover page compared with the last one, and any update to a listing-compliance deadline. Four of the six carry at least one dated obligation - September 4 and September 28 for Evogene, August 24 for Datavault AI, October 6 and February 1 for Accuray, and, for Flux Power, a covenant amendment that its most recent prospectus described as still under negotiation alongside a bid-price compliance period that began on July 24. Those dates exist whatever the quarter shows.